EMEA-001995-PIP01-16-M02

Key facts

Active substance
Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (JCAR017, lisocabtagene maraleucel)
Therapeutic area
Oncology
Decision number
P/0198/2019
PIP number
EMEA-001995-PIP01-16-M02
Pharmaceutical form(s)
Dispersion for infusion
Condition(s) / indication(s)
  • Treatment of B-lymphoblastic leukaemia/lymphoma
  • Treatment of mature B-cell neoplasms
Route(s) of administration
Intravenous use
Contact for public enquiries
Celgene Europe B.V.

Tel. +41 327298500
E-mail: medinfo.emea@celgene.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating